Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is pleased to announce the re-launch of its corporate website and the introduction of the newly created Careers section. Our goal is to enhance the job seekers’ experience with both active and passive candidate-centric features and advanced job search capabilities.

Working in partnership with iMarc, a full service firm, providing website strategy, design, and programming, the visitor experience was created to provide:

• Targeted job search functionality with personalized job management and candidate application tools
• Networking and candidate relationship building features
• An introduction to our employees inside and outside of work, highlighting the diversity of employee backgrounds and insight into professional development opportunities
• Access to our corporate video, illuminating the Cubist culture and the focus on improving health and saving lives
• Information on our Total Rewards philosophy
• Information on our recruitment programs

In addition to these enhancements, the design and interactive menus make navigation more intuitive and user-friendly.

Cubist is dedicated to continue improving resources for our web community, so expect to see more features implemented in the future. In addition, we value your comments and suggestions to help us understand your needs and improve our website. Please take a moment to provide your thoughts, ideas and suggestions on your Cubist website experience by completing our online survey here.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM® I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials — CONSERV™-1 and CONSERV™-2 — for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam’s RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist’s web site at www.cubist.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6060968&lang=en